ClinicalTrials.gg
CompletedNCT00914823Updated Jul 31, 2024

Kisspeptin Administration in the Adult

A Phase 1 interventional study of kisspeptin 112-121 and GnRH in Hypogonadotropic Hypogonadism, Kallmann Syndrome and GnRH Deficiency, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.

Primary conditionKallmann SyndromeRegistry: HypogonadismReclassifiedWhy we changed it
Registry
Hypogonadism — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kallmann Syndrome
Why
  1. The study's listed conditions name Kallmann Syndrome, a narrower term within Hypogonadism.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
256
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to learn about the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that causes the release of other hormones, including gonadotropin-releasing hormone (GnRH) in the body.

Read the detailed description

The reproductive hormone GnRH is essential for normal reproductive function. People with idiopathic hypogonadotropic hypogonadism (IHH), hyperprolactinemia, and polycystic ovarian syndrome (PCOS) do not secrete or respond to GnRH in a normal way. In this study, investigators will give participants kisspeptin-a hormone that is naturally found in the human body and is known to be a powerful stimulus of GnRH secretion. They may also give participants GnRH to determine if participants will be able to fully respond to kisspeptin. The goal of this study is to use kisspeptin administration to probe the condition of GnRH neurons in people with various reproductive disorders to better understand the underlying reasons for the disorders. Investigators hope to gain new insights into GnRH neuronal function (or dysfunction) that will lead to better diagnostics in the future.

02

Conditions studied

  • Hypogonadotropic Hypogonadism
  • Kallmann Syndrome
  • GnRH Deficiency
  • PCOS
  • Polycystic Ovarian Syndrome
  • Hyperprolactinemia

Browse trials for

Keywords

  • reproductive disorders
  • kisspeptin
  • hypogonadotropic hypogonadism
  • Kallmann Syndrome
  • PCOS
03

In context

Kallmann Syndrome Reclassified

23 studies on the registry are indexed under Kallmann Syndrome; 5 are open to participants now.

This study's enrollment of 256 is above the median of 75 across 14 interventional studies indexed under Kallmann Syndrome.

Browse Kallmann Syndrome studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.

Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Compared within Kallmann Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypogonadism. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

A. Healthy Subjects

All healthy subjects will meet the following criteria:

  • normal puberty with respect to onset and pace,
  • no chronic diseases,
  • no difficulty with blood draws,
  • no prescription medications for at least 2 months with the exception of seasonal allergy medications and hormone replacement therapy,
  • no illicit drug use or excessive alcohol consumption (\< 10 drinks/week),
  • no history of a medication reaction requiring emergency medical care,
  • normal physical exam and laboratory studies within protocol reference ranges.

Additional criteria based on subject population:

  1. Healthy Men:

    • between 21 and 40 years old,
    • normal erectile and ejaculatory function, no history of reproductive disorders,
    • testicular volume >15 ml.
  2. Healthy women:

    • between 21 and 40 years old,
    • not breastfeeding or pregnant,
    • menstrual cycles between 25 and 35 days in duration, at least 11 periods/year, with no more than 5 days variability in cycle duration,
    • no evidence for androgen excess (hirsutism or acne),
    • at screening, negative hCG pregnancy test,
    • negative screening for Factor V Leiden for those who might receive estradiol treatment as a part of this study.
  3. Healthy women:

    • between 50 and 60 years old,
    • no menstrual periods within the last year,
    • previous history of menstrual cycles between 25 and 35 days in duration, with no more than 5 days variability in cycle duration,
    • if applicable, able to undergo washout from hormone therapy,
    • no evidence for androgen excess (hirsutism or acne),
    • negative screening for Factor V Leiden for those who might receive estradiol treatment as a part of this study.

B. Subjects with Reproductive Disorders

All subjects with reproductive disorders will meet the following criteria:

  • 18 years or older,
  • all medical conditions stable and well controlled,
  • no prescription medications known to affect reproductive endocrine function for at least 2 months except for medications used to treat the subject's reproductive condition,
  • no history of a medication reaction requiring emergency medical care,
  • no illicit drug use or excessive alcohol consumption (\<10 drinks/week),
  • for women, not breastfeeding or pregnant,
  • if applicable, able to undergo appropriate from hormone therapy,
  • normal physical exam and laboratory studies within protocol reference ranges,
  • for women, at time of screening negative hCG pregnancy test.

Additional criteria based on subject population:

  1. Men and women with hypogonadotropic hypogonadism,

    • Confirmed diagnosis by low sex in the setting of low or inappropriately normal gonadotropins,
    • If needed, additional labs and imaging tests may be performed.
  2. Women with Polycystic Ovarian Syndrome (PCOS)

    • Confirmed diagnosis of PCOS,
    • If needed, additional labs and imaging tests may be performed.
  3. Men and women with hyperprolactinemia

    • confirmed diagnosis of elevated levels of prolactin measured via blood test,
    • no pituitary adenoma OR a microprolactinoma (\<10 mm). Patients with a macroprolactinoma confirmed on MRI imaging will be excluded,
    • willing to complete a dopamine agonist washout.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    kisspeptin, GnRH

    Intravenous (IV) or subcutaneous (SC) administration of kisspeptin 112-121 and/or administration of GnRH

    Drug: kisspeptin 112-121 · Drug: GnRH

Interventions

  • One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121

    Also known as: metastin 45-54

  • DrugGnRH

    One or more IV doses of GnRH, and/or SC administration of GnRH

    Also known as: gonadotropin-releasing hormone

06

What researchers measure

Primary outcomes

  1. Average change in luteinizing hormone (LH) in response to kisspeptin

    Time frame: Within 30 minutes of administration

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

References and documents

Publications

  • Lippincott MF, Leon S, Chan YM, Fergani C, Talbi R, Farooqi IS, Jones CM, Arlt W, Stewart SE, Cole TR, Terasawa E, Hall JE, Shaw ND, Navarro VM, Seminara SB. Hypothalamic Reproductive Endocrine Pulse Generator Activity Independent of Neurokinin B and Dynorphin Signaling. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4304-4318. doi: 10.1210/jc.2019-00146. PubMed 31132118 ↗
  • Chan YM, Lippincott MF, Butler JP, Sidhoum VF, Li CX, Plummer L, Seminara SB. Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2014 Dec;99(12):E2762-71. doi: 10.1210/jc.2014-2233. PubMed 25226293 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00914823
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Principal investigator
First posted
Jun 5, 2009
Start date
Jun 23, 2009
Primary completion
Oct 22, 2021
Completion
Oct 22, 2021
Last update
Jul 31, 2024

Study contacts

Stephanie B Seminara, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KISS1 protein, human

Start the discussion